Preparative regimens
| Preparative regimen . | SCT . | n . | Period . | Doses . |
|---|---|---|---|---|
| Cy/TBI | Auto | 43 | 1990-1999 | Cyclophosphamide 60 mg/kg per day (days −7, −6); TBI 12.0 Gy in 4 fractions (days −4 to −1). |
| R-Cy/TBI | Auto | 15 | 1999-2001 | Cyclophosphamide 60 mg/kg per day (days −7, −6); TBI 12.0 Gy in 4 fractions (days −4 to −1). |
| Rituximab 375 mg/m2 day 1 and 1000 mg/m2 day 8 of chemomobilization of stem cells. | ||||
| Rituximab 1000 mg/m2 days 1 and 8 after transplantation. | ||||
| R-BEAM | Auto | 23 | 2001-2007 | Carmustine 300 mg/m2 day −6; etoposide 200 mg/m2 twice daily (days −5 to −2); cytarabine 200 mg/m2 twice daily (days −5 to −2); melphalan 140 mg/m2 day −1. |
| Rituximab 375 mg/m2 day 1 and 1000 mg/m2 day 8 of chemomobilization of stem cells. | ||||
| Rituximab 1000 mg/m2 days 1 and 8 after transplantation. | ||||
| PFA | NST | 5 | 1997-2000 | Cisplatin 25 mg/m2 days −6 to −3; fludarabine 30 mg/m2 days −4 and −3; cytarabine 1 g/m2 days −4 and −3. |
| FCR | NST | 30 | 2000-2007 | Fludarabine 30 mg/m2 days −5 to − 3; cyclophosphamide 750 mg/m2 days −5 to −3; rituximab 375 mg/m2 day −13 and 1 g/m2 days −6, 1, 8. |
| Preparative regimen . | SCT . | n . | Period . | Doses . |
|---|---|---|---|---|
| Cy/TBI | Auto | 43 | 1990-1999 | Cyclophosphamide 60 mg/kg per day (days −7, −6); TBI 12.0 Gy in 4 fractions (days −4 to −1). |
| R-Cy/TBI | Auto | 15 | 1999-2001 | Cyclophosphamide 60 mg/kg per day (days −7, −6); TBI 12.0 Gy in 4 fractions (days −4 to −1). |
| Rituximab 375 mg/m2 day 1 and 1000 mg/m2 day 8 of chemomobilization of stem cells. | ||||
| Rituximab 1000 mg/m2 days 1 and 8 after transplantation. | ||||
| R-BEAM | Auto | 23 | 2001-2007 | Carmustine 300 mg/m2 day −6; etoposide 200 mg/m2 twice daily (days −5 to −2); cytarabine 200 mg/m2 twice daily (days −5 to −2); melphalan 140 mg/m2 day −1. |
| Rituximab 375 mg/m2 day 1 and 1000 mg/m2 day 8 of chemomobilization of stem cells. | ||||
| Rituximab 1000 mg/m2 days 1 and 8 after transplantation. | ||||
| PFA | NST | 5 | 1997-2000 | Cisplatin 25 mg/m2 days −6 to −3; fludarabine 30 mg/m2 days −4 and −3; cytarabine 1 g/m2 days −4 and −3. |
| FCR | NST | 30 | 2000-2007 | Fludarabine 30 mg/m2 days −5 to − 3; cyclophosphamide 750 mg/m2 days −5 to −3; rituximab 375 mg/m2 day −13 and 1 g/m2 days −6, 1, 8. |
Five patients underwent autologous SCT received regimens not listed in the table: BEAM (n = 3); busulfan and melphalan (n = 1); and thiotepa, busulfan, and cyclophosphamide (n = 1).
SCT indicates stem cell transplantation; Cy, cyclophosphamide; TBI, total body irradiation; R, rituximab; BEAM, carmustine, etoposide, cytarabine, and melphalan; NST, nonmyeloablative stem cell transplantation; PFA, cisplatin, fludarabine, and cytarabine; and FCR, fludarabine, cyclophosphamide, and rituximab.